Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To investigate the efficacy(HbA1c) at 6 months after adding basal insulin therapy (insulin
glargine) to dipeptidyl peptidase-IV (DPP-IV) and metformin plus or minus sulphonylurea
Secondary Objectives:
1. To assess the efficacy by adding insulin glargine
2. To assess insulin dose
3. Safety
Phase:
Phase 4
Details
Lead Sponsor:
Sanofi
Treatments:
Dipeptidyl-Peptidase IV Inhibitors Insulin Insulin Glargine Insulin, Globin Zinc Metformin